Literature DB >> 20862660

Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS.

J-H Chen1, R S Mehta, H-M Baek, K Nie, H Liu, M Q Lin, H J Yu, O Nalcioglu, M-Y Su.   

Abstract

This study investigated the association between the total choline (tCho) concentration and the clinical characteristics and biomarker status of breast cancer. Sixty-two patients with breast cancer, 1.5  cm or larger in size on MR images, were studied. The tCho concentration was correlated with the MRI features, contrast enhancement kinetics, clinical variables and biomarkers. Pairwise two-tailed Spearman's nonparametric test was used for statistical analysis. The tCho concentration was higher in high-grade than moderate-/low-grade tumors (p = 0.04) and in tumors with higher K(trans) and k(ep) (p < 0.001 for both). The association of tCho concentration with age (p = 0.05) and triple negative biomarker (p = 0.09) approached significance. tCho was not detected in 17 patients, including 15 with invasive ductal cancer and two with infiltrating lobular cancer. Fifteen of the 17 patients had moderate- to low-grade cancers, and 11 had human epidermal growth factor-2-negative cancer, suggesting that these two factors might lead to false-negative choline. Higher tCho concentration in high-grade tumors and tumors with higher K(trans) and k(ep) indicates that choline is associated with cell proliferation and tumor angiogenesis. The higher choline level in younger women may be caused by their more aggressive tumor type. The results presented here may aid in the better interpretation of (1)H MRS for the diagnosis of breast lesions.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20862660      PMCID: PMC3075960          DOI: 10.1002/nbm.1595

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  53 in total

1.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

Authors:  Bruce G Haffty; Qifeng Yang; Michael Reiss; Thomas Kearney; Susan A Higgins; Joanne Weidhaas; Lyndsay Harris; Willam Hait; Deborah Toppmeyer
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.

Authors:  Fusun Tokatli; Tokatli Fusun; Semsi Altaner; Altaner Semsi; Cem Uzal; Uzal Cem; Mevlut Ture; Ture Mevlut; Zafer Kocak; Kocak Zafer; Kazim Uygun; Uygun Kazim; Selcuk Bilgi; Bilgi Selcuk
Journal:  Exp Oncol       Date:  2005-06

4.  Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T.

Authors:  Hyun-Man Baik; Min-Ying Su; Hon Yu; Rita Mehta; Orhan Nalcioglu
Journal:  MAGMA       Date:  2006-05-09       Impact factor: 2.310

5.  Prognostic markers in triple-negative breast cancer.

Authors:  Emad A Rakha; Maysa E El-Sayed; Andrew R Green; Andrew H S Lee; John F Robertson; Ian O Ellis
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

Review 6.  Herceptin: mechanisms of action and resistance.

Authors:  Rita Nahta; Francisco J Esteva
Journal:  Cancer Lett       Date:  2006-02-08       Impact factor: 8.679

7.  Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.

Authors:  Lia Bartella; Elizabeth A Morris; D David Dershaw; Laura Liberman; Sunitha B Thakur; Chaya Moskowitz; Jennifer Guido; Wei Huang
Journal:  Radiology       Date:  2006-04-07       Impact factor: 11.105

Review 8.  Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions.

Authors:  Kristine Glunde; Ellen Ackerstaff; Noriko Mori; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Mol Pharm       Date:  2006 Sep-Oct       Impact factor: 4.939

9.  Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.

Authors:  Min-Ying Su; Hyun-Man Baik; Hon J Yu; Jeon-hor Chen; Rita S Mehta; Orhan Nalcioglu
Journal:  Technol Cancer Res Treat       Date:  2006-08

10.  The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies.

Authors:  Kalliopi P Siziopikou; Melody Cobleigh
Journal:  Breast       Date:  2006-11-13       Impact factor: 4.380

View more
  18 in total

1.  (1)H MR spectroscopy with external reference solution at 1.5 T for differentiating malignant and benign breast lesions: comparison using qualitative and quantitative approaches.

Authors:  Waka Mizukoshi; Eito Kozawa; Kaiji Inoue; Naoko Saito; Naoko Nishi; Toshiaki Saeki; Fumiko Kimura
Journal:  Eur Radiol       Date:  2012-07-10       Impact factor: 5.315

Review 2.  Choline metabolism in malignant transformation.

Authors:  Kristine Glunde; Zaver M Bhujwalla; Sabrina M Ronen
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

3.  Structural mass spectrometry of tissue extracts to distinguish cancerous and non-cancerous breast diseases.

Authors:  Kelly M Hines; Billy R Ballard; Dana R Marshall; John A McLean
Journal:  Mol Biosyst       Date:  2014-11

Review 4.  In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature.

Authors:  Jonathan K P Begley; Thomas W Redpath; Patrick J Bolan; Fiona J Gilbert
Journal:  Breast Cancer Res       Date:  2012-04-19       Impact factor: 6.466

5.  HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors.

Authors:  Ji Soo Choi; Hyeon-Man Baek; Suhkmann Kim; Min Jung Kim; Ji Hyun Youk; Hee Jung Moon; Eun-Kyung Kim; Kyung Hwa Han; Dong-Hyun Kim; Seung Il Kim; Ja Seung Koo
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Maria D Cao; Guro F Giskeødegård; Tone F Bathen; Beathe Sitter; Anna Bofin; Per E Lønning; Steinar Lundgren; Ingrid S Gribbestad
Journal:  BMC Cancer       Date:  2012-01-25       Impact factor: 4.430

Review 7.  Magnetic resonance in the detection of breast cancers of different histological types.

Authors:  Rebecca M Mayrhofer; Hsiao Piau Ng; Thomas C Putti; Philip W Kuchel
Journal:  Magn Reson Insights       Date:  2013-04-30

Review 8.  Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer.

Authors:  Egidio Iorio; Maria José Caramujo; Serena Cecchetti; Francesca Spadaro; Giulia Carpinelli; Rossella Canese; Franca Podo
Journal:  Front Oncol       Date:  2016-09-30       Impact factor: 6.244

9.  Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy.

Authors:  Ji Soo Choi; Hyeon-Man Baek; Suhkmann Kim; Min Jung Kim; Ji Hyun Youk; Hee Jung Moon; Eun-Kyung Kim; Youn Ki Nam
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

10.  Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI.

Authors:  Haesung Yoon; Dahye Yoon; Mijin Yun; Ji Soo Choi; Vivian Youngjean Park; Eun-Kyung Kim; Joon Jeong; Ja Seung Koo; Jung Hyun Yoon; Hee Jung Moon; Suhkmann Kim; Min Jung Kim
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.